Heron Therapeutics | HRTX - Current Assets

Stock Price
1.17
Daily Change
-0.10 -7.87%
Monthly
-21.48%
Yearly
-29.52%
Q1 Forecast
2.71

Heron Therapeutics reported $229.4M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
ALKERMES USD 1.74B 106.38M Sep/2025
Alnylam Pharmaceuticals USD 3.95B 309.11M Sep/2025
Amarin USD 628.33M 21.52M Sep/2025
ANI Pharmaceuticals USD 698.4M 95.77M Sep/2025
Anika Therapeutics USD 101.59M 2.27M Sep/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
Eisai JPY 840.88B 50.18B Dec/2025
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Heron Therapeutics USD 229.4M 18.48M Sep/2025
Insmed USD 1.93B 149.77M Sep/2025
Ligand Pharmaceuticals USD 753.92M 400.98M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 562.75M 182.86M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Surmodics USD 81.3M 948K Sep/2024
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Veracyte USD 449.22M 34.54M Sep/2025
Vertex Pharmaceuticals USD 10.57B 141.7M Sep/2025